Earlier this month, the FDA said compounded versions of semaglutide and similar drugs can be risky for patients because they are unapproved, meaning the agency does not review their safety, effectiveness and quality before they are put out in the market
Based on these concerns, what key aspects of patient education need to be addressed
Your provider matches the right one to your goal
doi: 10.3389/fphar.2025.1562896 Received 23 January 2025 Accepted 05 May 2025 Published 02 June 2025 Corrected 09 June 2025 Volume 16 - 2025 Edited by Ahmed Ghallab, Leibniz Research Centre for Working Environment and Human Factors (IfADo), Germany Reviewed by Madlen Matz-Soja, Leipzig University, Germany Mohamed Albadry, University Hospital Jena, Germany Updates Copyright 2025 Sun, Shang, Lv, Liu, Wu and Geng
Individuals with conditions like type 2 diabetes, where weight management is particularly challenging, can benefit significantly from semaglutide
Des tudes ont montr qu'environ six pour cent des personnes de 60 ans, aux tats-Unis et en Grande-Bretagne, ne sont pas suffisamment approvisionnes en vitamine B12
